Holen Sie sich die Stockscreener-App
0.7151
2.30%
0.0161
Handel nachbörslich:
.72
0.0049
+0.69%
Schlusskurs vom Vortag:
$0.699
Offen:
$0.68
24-Stunden-Volumen:
2.04M
Relative Volume:
2.45
Marktkapitalisierung:
$2.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-4.78%
1M Leistung:
-50.17%
6M Leistung:
-92.33%
1J Leistung:
-99.63%
1-Tages-Spanne:
$0.68
$0.89
1-Wochen-Bereich:
$0.65
$0.89
52-Wochen-Spanne:
$0.65
$213.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Firmenname
Cero Therapeutics Holdings Inc
Sektor
Branche
Telefon
650-407-2376
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Vergleichen Sie CERO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
0.7151 | 2.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Cero Therapeutics Holdings Inc Aktie (CERO) Neueste Nachrichten
CERo Therapeutics Delays Yearly Report Filing - TipRanks
FDA greenlights CERo’s Phase 1 trial for novel cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics Receives FDA Clearance For Second Clinical Trial Of CER-1236 In Solid Tumors - Nasdaq
CERo Gets FDA Clearance for CER-1236 Trial in Solid Tumors - MarketScreener
FDA greenlights CERo’s Phase 1 trial for novel cancer therapy - Investing.com India
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors - The Manila Times
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of - GlobeNewswire
Groundbreaking CAR-T Cancer Therapy Advances: FDA Greenlights Dual-Action Trial - Stock Titan
CERo Therapeutics gears up for clinical trial of cancer therapy By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.74 amid market challenges By Investing.com - Investing.com South Africa
CERO stock plunges to 52-week low at $0.74 amid market challenges - Investing.com Australia
CERo Therapeutics gears up for clinical trial of cancer therapy - Investing.com India
CERo Therapeutics Holdings, Inc. Poised to Initiate - GlobeNewswire
FDA Green Light: CERo's Leukemia Drug CER-1236 Advances to Human Trials with Optimized Manufacturing - Stock Titan
CERo Therapeutics (NASDAQ:CERO) Trading 4.6% Higher – Here’s What Happened - Defense World
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish - NewsBreak: Local News & Alerts
CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Ca - Asianet Newsable
CERO Flat on Leukemia Drug Developments - Baystreet.ca
CERo Therapeutics partners with UC Davis for AML trial By Investing.com - Investing.com South Africa
CERo Therapeutics partners with UC Davis for AML trial - Investing.com
Restaurant Brands International to Report First Quarter 2025 Results on May 8, 2025 - The Globe and Mail
CERo Therapeutics Announces Manufacturing Agreement with UC Davis Ahead of Phase 1 Clinical Trial for AML - Nasdaq
CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - GlobeNewswire
CERo Therapeutics reveals promising preclinical ovarian cancer study By Investing.com - Investing.com Australia
CERo Therapeutics reports positive preclinical results for cancer treatment By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Understanding CERO’s financial ratios: A beginner’s guide - US Post News
CERo Therapeutics Holdings, Inc. Presents Encouraging - GlobeNewswire
CERo Therapeutics reveals promising preclinical ovarian cancer study - Investing.com
CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting - The Manila Times
Looking for Exposure to NFLX? Try These Two ETFs - The Globe and Mail
CERo Therapeutics reports positive preclinical results for cancer treatment - Investing.com India
CERo Therapeutics Announces Promising Preclinical Results for CER-1236 in Ovarian Cancer at 2025 SITC Spring Scientific Presentation - Nasdaq
Breakthrough: CERo's Novel Cancer Treatment Targets Ovarian Cancer With Zero Toxicity - StockTitan
CERO stock plunges to 52-week low at $1.31 amid market challenges - Investing.com Australia
CERO stock plunges to 52-week low at $1.31 amid market challenges By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
CERo Therapeutics Holdings, Inc. Announces Progress in - GlobeNewswire
Will This New AML Treatment Strategy Transform Blood Cancer Therapy? CERo Takes Critical Step - StockTitan
CERo Therapeutics to Present Preclinical Data on CER-1236 for Ovarian Cancer at SITC Conference - Nasdaq
CERo Therapeutics Holdings, Inc. to Present Data at the - GlobeNewswire
Can CERo's Cancer-Fighting T Cells Transform Ovarian Cancer Treatment? New Data Coming March - StockTitan
3 Companies Buying Back Stock – Why They’re Doubling Down - The Globe and Mail
CERO stock touches 52-week low at $1.52 amid market challenges - Investing.com Canada
CERO stock touches 52-week low at $1.52 amid market challenges By Investing.com - Investing.com South Africa
Finanzdaten der Cero Therapeutics Holdings Inc-Aktie (CERO)
Es liegen keine Finanzdaten für Cero Therapeutics Holdings Inc (CERO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Cero Therapeutics Holdings Inc-Aktie (CERO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| YK Bioventures Opportunities G | 10% Owner |
Dec 12 '24 |
Sale |
0.07 |
1,614,541 |
113,018 |
16,004,077 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 11 '24 |
Sale |
0.08 |
1,343,801 |
107,504 |
17,618,618 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 06 '24 |
Sale |
0.12 |
1,236,874 |
148,425 |
21,383,909 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 10 '24 |
Sale |
0.09 |
1,570,947 |
141,385 |
18,962,419 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 09 '24 |
Sale |
0.11 |
850,543 |
93,560 |
20,533,366 |
| SLOAN STUART M | 10% Owner |
Sep 25 '24 |
Sale |
0.10 |
532,486 |
55,538 |
21,067,956 |
| YK Bioventures Opportunities G | 10% Owner |
Oct 10 '24 |
Sale |
0.10 |
3,250,000 |
325,000 |
22,620,783 |
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):